We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
OpGen Inc | NASDAQ:OPGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.076 | 18.58% | 0.485 | 0.4116 | 0.485 | 0.485 | 0.406 | 0.4357 | 408,302 | 23:20:38 |
Conference Call Details | |
U.S. Dial-in Number: | +1 (844) 420-8185 |
International Dial-in Number: | +1 (216) 562-0481 |
Webcast: | https://edge.media-server.com/mmc/p/iggnmjim |
Conference ID: | 8595009 |
Reply Details | |
U.S. Dial-in Number: | +1 (855) 859-2056 |
International Dial-in Number: | +1 (404) 537-3406 |
Conference ID: | 8595009 |
Following the conclusion of the conference call, a replay will be available through May 14, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen is developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For more information, please visit www.opgen.com.
OpGen:Oliver SchachtPresident and CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew Bretzius FischTank Marketing and PRmatt@fischtankpr.com
OpGen Investor Contact:Joe GreenEdison Group jgreen@edisongroup.com
1 Year OpGen Chart |
1 Month OpGen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions